{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-285963","form_type":"8-K/A","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2022-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.654277+00:00","generated_at":"2026-06-21T17:32:57.995199+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Imara sells PDE9 program (tovinontrine) to Cardurion for $35M upfront plus milestones","bullets":["Upfront cash of $34.75M at closing plus $250K previously received; net proceeds ~$32.75M after ~$2M costs.","Potential milestone payments: $10M for clinical proof-of-concept, $50M for regulatory/commercial events.","Pro forma cash at Sep 30, 2022 rises to $82.2M; net loss for 9M 2022 falls from $30.7M to $13.0M.","R&D expenses eliminated from $18.8M to $1.1M for 9M 2022 as sold asset costs are removed.","Imara retains no further involvement in development or commercialization of the sold assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-285963","json":"https://secwatch.observer/filing/0001193125-22-285963.json","markdown":"https://secwatch.observer/filing/0001193125-22-285963.md","text":"https://secwatch.observer/filing/0001193125-22-285963.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522285963/0001193125-22-285963-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522285963/d408792d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T17:32:57.995199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}